Champions Oncolog Cmn (CSBR) 1.99 $CSBR
Champions Oncology Announces Revenue Up 26%, Projects 43% - 60% Growth For Current Fiscal Year
PR Newswire - Thu Jul 28, 7:00AM CDT
Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the year ended April 30, 2016.
CSBR: 1.99 (+0.17)
Champions Oncology, Inc. Announces Closing of Public Offering of Common Stock
PR Newswire - Wed Jun 15, 11:00AM CDT
Champions Oncology, Inc. (NASDAQ: CSBR), or the "Company", a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the closing of its previously announced underwritten public offering of 2,000,000 registered shares of its common stock, par value $0.001 per share, at an offering price of $2.25 per share. In addition, the Company announced today the partial exercise of the over-allotment option granted to the underwriter to purchase an additional 258,749 shares of its common stock at the public offering price. All of the shares have been offered by the Company. The shares of Champions Oncology, Inc. are currently trading on NASDAQ under the symbol "CSBR".
CSBR: 1.99 (+0.17), NHLD: 3.12 (+0.02)
Champions Oncology, Inc. Announces Pricing of Public Offering of Common Stock
PR Newswire - Thu Jun 09, 6:30PM CDT
Champions Oncology, Inc. (NASDAQ: CSBR), or the "Company", a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the pricing of its previously announced underwritten public offering. The Company is offering 2,000,000 registered shares of its common stock, par value $0.001 per share, at an offering price of $2.25 per share. In addition, Champions Oncology, Inc. has granted the underwriter a 45-day over-allotment option to purchase up to 300,000 additional shares of common stock at the public offering price. All of the shares are being offered by the Company. The shares of Champions Oncology, Inc. are currently trading on NASDAQ under the symbol "CSBR".
CSBR: 1.99 (+0.17), NHLD: 3.12 (+0.02)
Champions Oncology Announces Addition to Board of Directors
PR Newswire - Tue Apr 12, 11:30AM CDT
Champions Oncology, Inc. (NASDAQ:CSBR) is pleased to announce the appointment of Dr. Philip Breitfeld to its Board of Directors. Dr. Breitfeld has more than 30 years of experience in oncology. His appointment will further the company's efforts to accelerate growth and increase the adoption of its technology platform.
CSBR: 1.99 (+0.17)
Champions Oncology Reports Results for the Third Quarter Ended January 31, 2016
PR Newswire - Tue Mar 15, 7:30AM CDT
Champions Oncology, Inc. (NASDAQ: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the third quarter ended January 31, 2016.
CSBR: 1.99 (+0.17)
Champions To Present at the 28th Annual ROTH Capital Conference on March 16, 2016
PR Newswire - Fri Mar 11, 8:00AM CST
Champions Oncology (CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will be presenting at the 28th Annual ROTH Capital Conference on Wednesday, March 16, 2016. The Conference will be held at the Ritz Carlton in Dana Point, California from March 13 - 16, 2016.
CSBR: 1.99 (+0.17)
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 15, 2016
PR Newswire - Thu Mar 10, 9:00AM CST
Champions Oncology (NASDAQ: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the third quarter ended January 31, 2016, on Tuesday, March 15, 2016, before the market open.
CSBR: 1.99 (+0.17)
Champions Oncology begins prospective correlative trial in sarcoma patients
M2 - Fri Jan 22, 3:09AM CST
Oncology drug company Champions Oncology (NasdaqCM:CSBR) disclosed on Thursday theat it has launched a sponsored prospective correlative trial of patient derived xenograft modeling (PDX or Champions TumorGraft PDX models) in patients with metastatic or recurrent sarcoma.
CSBR: 1.99 (+0.17)
Champions Oncology Announces Initiation of Prospective Correlative Trial in Sarcoma
PR Newswire - Thu Jan 21, 10:00AM CST
Champions Oncology (NASDAQ:CSBR) today announced that it has initiated a sponsored prospective correlative trial of patient derived xenograft modeling (PDX or Champions TumorGraft® PDX models) in patients with metastatic or recurrent sarcoma. Mount Sinai Hospital in Toronto, Canada is the first clinical site to enroll patients in the newly-opened study.
CSBR: 1.99 (+0.17)
Champions Oncology Reports Results for the Second Quarter Ended October 31, 2015
PR Newswire - Mon Dec 14, 3:50PM CST
Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the second quarter ended October 31, 2015.
CSBR: 1.99 (+0.17)
Champions Oncology Signs Deal to Expand Technology Platform into AML
PR Newswire - Mon Dec 14, 3:01PM CST
Champions Oncology, Inc. (CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that it signed an agreement with a top 20 global pharmaceutical company to develop a novel process for establishing hematology models. The initial agreement will provide near-term revenue for the Company, as well as result in a longer-term revenue growth stream.
CSBR: 1.99 (+0.17)
Champions Oncology to Announce Second Quarter Financial Results on Monday, December 14, 2015
PR Newswire - Thu Dec 10, 9:45AM CST
Champions Oncology (CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the second quarter ended October 31, 2015, on Monday, December 14, 2015, after the market close.
CSBR: 1.99 (+0.17)
Champions Oncology to Present at LD MICRO Investor Conference
PR Newswire - Mon Nov 30, 10:51AM CST
Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that Joel Ackerman, Chief Executive Officer, will be presenting at the LD MICRO Investor Conference on Wednesday, December 2, 2015 at 4:30pm Pacific Standard Time (PST). The conference, held at the Luxe Sunset Bel Air Hotel in Los Angeles, CA, will feature 200 small/micro-cap companies and is expected to host more than 1,000 portfolio managers, research analysts and other investors.
CSBR: 1.99 (+0.17)
Champions Oncology Reports Results for the First Quarter Ended July 31, 2015
PR Newswire - Thu Sep 10, 3:05PM CDT
Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the first quarter ended July 31, 2015.
CSBR: 1.99 (+0.17)
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2015
PR Newswire - Tue Sep 08, 9:30AM CDT
Champions Oncology (CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2015, on Thursday, September 10, 2015, after the market close.
CSBR: 1.99 (+0.17)
Champions Oncology files two patents with USPTO for use of PDX platform in immune-oncology
M2 - Tue Aug 18, 3:01AM CDT
Oncology drugs company Champions Oncology (OtherOTC:CSBR) disclosed on Monday that it has submitted two patent applications to the US Patent and Trademark Office (USPTO) with respect to the development and use of mice with humanized immune systems to test immune-oncology drugs and therapeutic cancer vaccines with its Champions TumorGraft platform.
CSBR: 1.99 (+0.17)
Champions Oncology Files Patents for Use of PDX Platform in Immune-Oncology
PR Newswire - Mon Aug 17, 8:11AM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that it has filed two patent applications with the United States Patent and Trademark Office (USPTO) relating to the development and use of mice with humanized immune systems to test immune-oncology drugs and therapeutic cancer vaccines.
CSBR: 1.99 (+0.17)
/C O R R E C T I O N -- Champions Oncology, Inc./
PR Newswire - Wed Aug 12, 8:25AM CDT
In the news release, Champions Oncology Announces Reverse Stock Split in Preparation for Uplisting to NASDAQ, issued 12-Aug-2015 by Champions Oncology, Inc. over PR Newswire, we are advised by the company that the first paragraph, last sentence, should read "August 12, 2015" rather than "August 10, 2015" as originally issued inadvertently. The complete, corrected release follows:
CSBR: 1.99 (+0.17)
Champions Oncology Announces Reverse Stock Split in Preparation for Uplisting to NASDAQ
PR Newswire - Wed Aug 12, 7:00AM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced a 1-for-12 reverse stock split of the Company's authorized, issued and outstanding common stock. The reverse stock split is in preparation for the Company's proposed listing of its common stock on the NASDAQ Capital Market. The company's common stock will begin trading on a post-split basis at the opening of trading on August 10, 2015.
CSBR: 1.99 (+0.17)
Champion Oncology Announces Additions to Leadership Team to Support Continued Growth
PR Newswire - Wed Aug 05, 1:00PM CDT
Champions Oncology, Inc. (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that David DeOrnellis joined the organization as Global Director of Laboratory Operations; Mark Weinstein assumed the role of Chief Information Officer; and Jordan Rubinson was named Chief Commercial Officer.
CSBR: 1.99 (+0.17), NVS: 81.34 (-0.60)
Champions Oncology Announces Revenue Up 26%, Projects 43% - 60% Growth For Current Fiscal Year
PR Newswire - Thu Jul 28, 7:00AM CDT
Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the year ended April 30, 2016.
CSBR: 1.99 (+0.17)
Champions Oncology, Inc. Announces Closing of Public Offering of Common Stock
PR Newswire - Wed Jun 15, 11:00AM CDT
Champions Oncology, Inc. (NASDAQ: CSBR), or the "Company", a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the closing of its previously announced underwritten public offering of 2,000,000 registered shares of its common stock, par value $0.001 per share, at an offering price of $2.25 per share. In addition, the Company announced today the partial exercise of the over-allotment option granted to the underwriter to purchase an additional 258,749 shares of its common stock at the public offering price. All of the shares have been offered by the Company. The shares of Champions Oncology, Inc. are currently trading on NASDAQ under the symbol "CSBR".
CSBR: 1.99 (+0.17), NHLD: 3.12 (+0.02)
Champions Oncology, Inc. Announces Pricing of Public Offering of Common Stock
PR Newswire - Thu Jun 09, 6:30PM CDT
Champions Oncology, Inc. (NASDAQ: CSBR), or the "Company", a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the pricing of its previously announced underwritten public offering. The Company is offering 2,000,000 registered shares of its common stock, par value $0.001 per share, at an offering price of $2.25 per share. In addition, Champions Oncology, Inc. has granted the underwriter a 45-day over-allotment option to purchase up to 300,000 additional shares of common stock at the public offering price. All of the shares are being offered by the Company. The shares of Champions Oncology, Inc. are currently trading on NASDAQ under the symbol "CSBR".
CSBR: 1.99 (+0.17), NHLD: 3.12 (+0.02)
Champions Oncology Announces Addition to Board of Directors
PR Newswire - Tue Apr 12, 11:30AM CDT
Champions Oncology, Inc. (NASDAQ:CSBR) is pleased to announce the appointment of Dr. Philip Breitfeld to its Board of Directors. Dr. Breitfeld has more than 30 years of experience in oncology. His appointment will further the company's efforts to accelerate growth and increase the adoption of its technology platform.
CSBR: 1.99 (+0.17)
Champions Oncology Reports Results for the Third Quarter Ended January 31, 2016
PR Newswire - Tue Mar 15, 7:30AM CDT
Champions Oncology, Inc. (NASDAQ: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the third quarter ended January 31, 2016.
CSBR: 1.99 (+0.17)
Champions To Present at the 28th Annual ROTH Capital Conference on March 16, 2016
PR Newswire - Fri Mar 11, 8:00AM CST
Champions Oncology (CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will be presenting at the 28th Annual ROTH Capital Conference on Wednesday, March 16, 2016. The Conference will be held at the Ritz Carlton in Dana Point, California from March 13 - 16, 2016.
CSBR: 1.99 (+0.17)
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 15, 2016
PR Newswire - Thu Mar 10, 9:00AM CST
Champions Oncology (NASDAQ: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the third quarter ended January 31, 2016, on Tuesday, March 15, 2016, before the market open.
CSBR: 1.99 (+0.17)
Champions Oncology begins prospective correlative trial in sarcoma patients
M2 - Fri Jan 22, 3:09AM CST
Oncology drug company Champions Oncology (NasdaqCM:CSBR) disclosed on Thursday theat it has launched a sponsored prospective correlative trial of patient derived xenograft modeling (PDX or Champions TumorGraft PDX models) in patients with metastatic or recurrent sarcoma.
CSBR: 1.99 (+0.17)
Champions Oncology Announces Initiation of Prospective Correlative Trial in Sarcoma
PR Newswire - Thu Jan 21, 10:00AM CST
Champions Oncology (NASDAQ:CSBR) today announced that it has initiated a sponsored prospective correlative trial of patient derived xenograft modeling (PDX or Champions TumorGraft® PDX models) in patients with metastatic or recurrent sarcoma. Mount Sinai Hospital in Toronto, Canada is the first clinical site to enroll patients in the newly-opened study.
CSBR: 1.99 (+0.17)
Champions Oncology Reports Results for the Second Quarter Ended October 31, 2015
PR Newswire - Mon Dec 14, 3:50PM CST
Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the second quarter ended October 31, 2015.
CSBR: 1.99 (+0.17)
Champions Oncology Signs Deal to Expand Technology Platform into AML
PR Newswire - Mon Dec 14, 3:01PM CST
Champions Oncology, Inc. (CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that it signed an agreement with a top 20 global pharmaceutical company to develop a novel process for establishing hematology models. The initial agreement will provide near-term revenue for the Company, as well as result in a longer-term revenue growth stream.
CSBR: 1.99 (+0.17)
Champions Oncology to Announce Second Quarter Financial Results on Monday, December 14, 2015
PR Newswire - Thu Dec 10, 9:45AM CST
Champions Oncology (CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the second quarter ended October 31, 2015, on Monday, December 14, 2015, after the market close.
CSBR: 1.99 (+0.17)
Champions Oncology to Present at LD MICRO Investor Conference
PR Newswire - Mon Nov 30, 10:51AM CST
Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that Joel Ackerman, Chief Executive Officer, will be presenting at the LD MICRO Investor Conference on Wednesday, December 2, 2015 at 4:30pm Pacific Standard Time (PST). The conference, held at the Luxe Sunset Bel Air Hotel in Los Angeles, CA, will feature 200 small/micro-cap companies and is expected to host more than 1,000 portfolio managers, research analysts and other investors.
CSBR: 1.99 (+0.17)
Champions Oncology Reports Results for the First Quarter Ended July 31, 2015
PR Newswire - Thu Sep 10, 3:05PM CDT
Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the first quarter ended July 31, 2015.
CSBR: 1.99 (+0.17)
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2015
PR Newswire - Tue Sep 08, 9:30AM CDT
Champions Oncology (CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2015, on Thursday, September 10, 2015, after the market close.
CSBR: 1.99 (+0.17)
Champions Oncology files two patents with USPTO for use of PDX platform in immune-oncology
M2 - Tue Aug 18, 3:01AM CDT
Oncology drugs company Champions Oncology (OtherOTC:CSBR) disclosed on Monday that it has submitted two patent applications to the US Patent and Trademark Office (USPTO) with respect to the development and use of mice with humanized immune systems to test immune-oncology drugs and therapeutic cancer vaccines with its Champions TumorGraft platform.
CSBR: 1.99 (+0.17)
Champions Oncology Files Patents for Use of PDX Platform in Immune-Oncology
PR Newswire - Mon Aug 17, 8:11AM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that it has filed two patent applications with the United States Patent and Trademark Office (USPTO) relating to the development and use of mice with humanized immune systems to test immune-oncology drugs and therapeutic cancer vaccines.
CSBR: 1.99 (+0.17)
/C O R R E C T I O N -- Champions Oncology, Inc./
PR Newswire - Wed Aug 12, 8:25AM CDT
In the news release, Champions Oncology Announces Reverse Stock Split in Preparation for Uplisting to NASDAQ, issued 12-Aug-2015 by Champions Oncology, Inc. over PR Newswire, we are advised by the company that the first paragraph, last sentence, should read "August 12, 2015" rather than "August 10, 2015" as originally issued inadvertently. The complete, corrected release follows:
CSBR: 1.99 (+0.17)
Champions Oncology Announces Reverse Stock Split in Preparation for Uplisting to NASDAQ
PR Newswire - Wed Aug 12, 7:00AM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced a 1-for-12 reverse stock split of the Company's authorized, issued and outstanding common stock. The reverse stock split is in preparation for the Company's proposed listing of its common stock on the NASDAQ Capital Market. The company's common stock will begin trading on a post-split basis at the opening of trading on August 10, 2015.
CSBR: 1.99 (+0.17)
Champion Oncology Announces Additions to Leadership Team to Support Continued Growth
PR Newswire - Wed Aug 05, 1:00PM CDT
Champions Oncology, Inc. (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that David DeOrnellis joined the organization as Global Director of Laboratory Operations; Mark Weinstein assumed the role of Chief Information Officer; and Jordan Rubinson was named Chief Commercial Officer.
CSBR: 1.99 (+0.17), NVS: 81.34 (-0.60)
